Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-6096 for episodic migraine prophylaxis
NCT01513291Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2012
- Primary completion
- Oct 2012
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of filorexant in episodic migraine, sponsored by Merck & Co. Started Feb 2012; status: completed.
02
Drugs
filorexant
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT01513291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01513291.